U.S. Markets closed

Cumberland Pharmaceuticals Inc. (CPIX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.6500-0.0250 (-0.93%)
At close: 4:00PM EDT

Cumberland Pharmaceuticals Inc.

2525 West End Avenue
Suite 950
Nashville, TN 37203
United States
615 255 0068

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees90

Key Executives

NameTitlePayExercisedYear Born
Mr. A. J. KazimiFounder, Chairman, Pres & CEO787kN/A1958
Mr. Michael P. BonnerCFO and Sr. Director of Fin. & Accounting240.52kN/A1977
Mr. Leo B. PavlivExec. VP of Operations & Chief Devel. Officer490.24kN/A1961
Mr. James Lowrance HermanSr. VP of National Accounts & Chief Compliance Officer310.65kN/A1955
Mr. Martin E. CearnalExec. VP, Chief Commercial Officer & Director381.74kN/A1945
Ms. Jean W. MarstillerSr. VP of Admin. Services & Corp. Sec.N/AN/A1950
Ms. Cindy B. PattonSr. Director of Field MarketingN/AN/A1953
Mr. John Michael HammDirector of Corp. Devel.N/AN/A1934
Mr. Adam S. MostafaManaging DirectorN/AN/A1980
Ms. Erin Smith GullSr. Corp. Relations AssociateN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and rheumatology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ injection, for the treatment of certain serious bacterial infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. The company markets and sells its products through sales representatives and district managers. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Corporate Governance

Cumberland Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.